| Revista: | Genetics and molecular biology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000459185 |
| ISSN: | 1415-4757 |
| Autors: | Sun, Zhuo1 Fan, Jinbo1 Dang, Yixiong3 Zhao, Yufeng2 |
| Institucions: | 1Xi’an Medical University, Xi’an Key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi’an, Shaanxi. China 2Institute of Basic Medical Sciences, Weiyang District, Shaanxi. China 3Xi’an Medical University, School of Public Health, Xi’an, Shaanxi. China |
| Any: | 2023 |
| Volum: | 46 |
| Número: | 3 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Descriptivo |
| Resumen en inglés | Enhancers are essential cis-acting regulatory elements that determine cell identity and tumor progression. Enhancer function is dependent on the physical interaction between the enhancer and its target promoter inside its local chromatin environment. Enhancer reprogramming is an important mechanism in cancer pathogenesis and can be driven by both cis and trans factors. Super enhancers are acquired at oncogenes in numerous cancer types and represent potential targets for cancer treatment. BET and CDK inhibitors act through mechanisms of enhancer function and have shown promising results in therapy for various types of cancer. Genome editing is another way to reprogram enhancers in cancer treatment. The relationship between enhancers and cancer has been revised by several authors in the past few years, which mainly focuses on the mechanisms by which enhancers can impact cancer. Here, we emphasize SE’s role in cancer pathogenesis and the new therapies involving epigenetic regulators (BETi and CDKi). We suggest that understanding mechanisms of activity would aid clinical success for these anti-cancer agents |
| Disciplines | Medicina |
| Paraules clau: | Oncología, Tratamiento, Potenciadores, Patogénesis, Cáncer |
| Keyword: | Oncology, Treatment, Cancer, Enhancers, Pathogenesis |
| Text complet: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
